Full Press Release Details
FOSTER CITY, Calif., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that it will release its fourth quarter and full year 2025 financial results and business highlights before the market opens on Wednesday, February 25, 2026 via press release, which will be available on theInvestors and Mediasection of the Company’s website. Geron will host a conference call and webcast at 8:00 a.m. Eastern Time.
A live and archived audio webcast of the conference call will be available from theInvestors and Mediasection of the Company’s website at www.geron.com.
About GeronGeron is a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer. Our first-in-class telomerase inhibitor RYTELO®(imetelstat) is approved in the United States and the European Union for the treatment of certain adult patients with LR-MDS with transfusion-dependent anemia. We are also conducting a pivotal Phase 3 clinical trial of imetelstat in JAK-inhibitor R/R MF, as well as studies in other hematologic malignancies. Inhibiting telomerase activity, which is increased in malignant stem and progenitor cells in the bone marrow, aims to potentially reduce proliferation and induce death of malignant cells. To learn more, visitwww.geron.comorLinkedIn.